ArticleJournal of thoracic disease2025
Lung-protective effects of esketamine in patients undergoing video-assisted thoracoscopic surgery: a randomized controlled trial.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Video-assisted thoracoscopic surgery (VATS) is associated with pulmonary function impairment due to the nature of the surgical site. The use of esketamine, which acts on multiple receptors, has become widespread in general anesthesia, but its function in pulmonary protection remains unclear. We examined whether esketamine can improve pulmonary function during VATS, further investigated the underlying mechanisms of its effect, and evaluated its dose-effect relationship. Methods: Patients aged 18-65 years scheduled for VATS were included in the study. Patients were assigned randomly to the low-dose esketamine group (group K1), high-dose esketamine group (group K2), or control group (group C). The primary outcome was arterial-alveolar oxygen partial pressure ratio (a/A ratio). The secondary outcomes included other pulmonary parameters, intraoperative hemodynamics, adverse events, postoperative pain scores, inflammatory biomarkers, and postoperative pulmonary complications (PPCs). Results: In total, 145 eligible patients were enrolled in the study. Compared with the patients in the esketamine groups, those in the control group had a lower a/A ratio and oxygenation index (OI), a higher respiratory index (RI) and alveolar-arterial partial pressure difference of oxygen (A-aDO Conclusions: Esketamine administration was effective in protecting pulmonary function in patients undergoing VATS by ameliorating oxygenation and reducing hemodynamic fluctuation and postoperative pain. However, the relationship between the optimal dosage and minimal adverse events requires further investigation. Trial Registration: This randomized controlled trial was registered in the Chinese Clinical Trials Registry (registration No. ChiCTR2100051518).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.